National Institute of Allergy and Infectious Diseases
Link to NIAID Home Page Link to NIAID Home Page Link to NIH Home Page
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

Biodefense and Related Programs
 Biodefense
  About
  For Researchers
   Introduction
   Category A-C Pathogens
   Immunology of Biodefense
   Resources
   Funding
    FY2003 Awards
    FY2004 Awards
    FY2005 Awards
    FY2006 Awards
    FY2007 Awards
   Meetings
  Public and Media
 Radiation Countermeasures
 Chemical Countermeasures


Biodefense

Biodefense Grants and Contracts:
FY2006 Awards

In fiscal year (FY) 2006, NIAID awarded a number of grants and contracts to expand scientific research and development for biodefense. These initiatives have been categorized according to the following four areas:

  • Basic Research—programs to investigate pathogen biology, host response, microbial genomic sequencing, and proteomics
  • Product Development—initiatives to support all phases of development of a candidate product or platform technology, including development of vaccines, therapeutics, and diagnostics
  • Clinical Research—initiatives to evaluate biodefense therapies, vaccines, and diagnostics
  • Research Resources—initiatives to build biodefense research capacity and infrastructure

Details concerning specific initiatives and related award information may be found below.

Basic Research

Biodefense and Emerging Infectious Diseases Research Opportunities

Objective: To encourage the submission of investigator-initiated research grant applications in biodefense and select emerging infectious diseases. The goal is to expedite research leading to the diagnosis, prevention, and treatment of diseases caused by potential bioterrorism agents.
Contact Info
Dr. Samuel Perdue
E-mail: sp189u@nih.gov

Innate Immunity to NIAID Category B Protozoa

Objective: To discover the cellular/molecular/biochemical mechanisms by which the mammalian innate immune system responds to NIAID Category B Priority Pathogens.
Contact Info
Tonu Wali
E-mail: twali@niaid.nih.gov

Training and Career Development for Biodefense and Emerging Diseases

Objective: To ensure that an adequate cadre of well-trained and motivated investigators are available to pursue research and development objectives in biodefense and emerging diseases.
Contact Info
Dr. Susan Garges
E-mail: sgarges@niaid.nih.gov

Product Development

Assays for Influenza Therapeutics: Project BioShield

Objective: To develop high-throughput in vitro screening assays for influenza antiviral therapeutics incorporating validated, high-priority, biochemical targets.
Contact Info
Karen Lacourciere
E-mail: lacourcierek@niaid.nih.gov

Cooperative Research Partnerships for Biodefense

Objective: To support the discovery, design, and development of vaccines, therapeutics, adjuvants, and diagnostics for NIAID Category A, B, and C priority pathogens and toxins.
Contact Info
General scientific, technical, and programmatic issues: Michael Schaefer
E-mail: mschaefer@niaid.nih.gov
Vaccines: Lanling Zou
E-mail: lanlingz@niaid.nih.gov
Adjuvants: David Winter
E-mail: dwinter@niaid.nih.gov
Therapeutics: Mark Challberg
E-mail: mchallberg@niaid.nih.gov
Immunotherapeutics: Alison Deckhut
E-mail: adeckhut@niaid.nih.gov
Diagnostics: Maria Giovanni
E-mail: MGiovanni@niaid.nih.gov

Development of Therapeutic Agents for Selected Viral Diseases

Objective: To develop new, safe, and effective therapeutics for Variola major and viral hemorrhagic fevers, viral encephalitides, and influenza.
Contact Info
Dr. Katherine Taylor
E-mail: kataylor@niaid.nih.gov

Neutralizing Monoclonal Antibodies for Type A Botulinum Neurotoxins

Objective: Formulate a mixture of three human-compatible monoclonal antibodies to be evaluated as a treatment for exposure to botulinum neurotoxin serotypes A1 and A2. The contract also includes the performance of investigational new drug-enabling studies and long-term stability bulk drug substance and final drug product.
Contact Info
Dr. Katherine Taylor
E-mail: kataylor@niaid.nih.gov

NIAID Small Business Biodefense Program

Objective: To encourage Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) applications to develop therapeutics, vaccines, adjuvants/immunostimulants, diagnostics, and selected resources for biodefense.
Contact Info
Dr. Barbara Mulach
E-mail: bmulach@nih.gov

Clinical Research

NIAID Clinical Trial Planning (R34) Grants

Objective: To support planning, design of, and documentation for investigator-initiated Phase I, II, III, and IV clinical trials.
Contact Info
Division of AIDS: Karen Reese
E-mail: kreese@niaid.nih.gov
Division of Allergy, Immunology, and Transplantation: Josiah Wedgwood
E-mail: JWedgwood@niaid.nih.gov
Division of Microbiology and Infectious Diseases: Shy Shorer
E-mail: shorers@niaid.nih.gov

Research Resources

NBL Operations Cooperative Agreements

Objective: To support operations of NIAID National Biocontainment Laboratories (NBL).
Contact Info
Rona Hirschberg
E-mail: rhirschberg@niaid.nih.gov

Services for Pre-Clinical Development of Therapeutic Agents

Objective: To establish a resource to facilitate preclinical development of therapeutic agents (drugs or biological products), including activities required for Investigational New Drug applications.
Contact Info
Beth Spinelli
E-mail: spinellb@niaid.nih.gov

back to top


See Also

List of FY 2005 Awards

List of FY 2004 Awards

List of FY 2003 Awards

For information on awards related to radiation and nuclear threats, please visit the Medical Countermeasures Against Radiation and Nuclear Threats FY06 grants and contracts awards Web pages.

For more information on the NIAID drug development contracts, please see NIAID Awards $212 Million to Advance Biodefense Therapeutics.

E-mail Icon E-mail this page
Print Icon Print this page

See Also

List of FY 2005 Awards

List of FY 2004 Awards

List of FY 2003 Awards

For information on awards related to radiation and nuclear threats, please visit the Medical Countermeasures Against Radiation and Nuclear Threats FY06 grants and contracts awards Web pages.

For more information on the NIAID drug development contracts, please see NIAID Awards $212 Million to Advance Biodefense Therapeutics.